119 related articles for article (PubMed ID: 12409656)
1. Vascular endothelial growth factor as a target opportunity in hematological malignancies.
Bellamy WT
Curr Opin Oncol; 2002 Nov; 14(6):649-56. PubMed ID: 12409656
[TBL] [Abstract][Full Text] [Related]
2. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.
Dvorak HF
J Clin Oncol; 2002 Nov; 20(21):4368-80. PubMed ID: 12409337
[TBL] [Abstract][Full Text] [Related]
3. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
Giles FJ
Oncologist; 2001; 6 Suppl 5():32-9. PubMed ID: 11700390
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic and lymphangiogenic molecules in hematological malignancies.
Orpana A; Salven P
Leuk Lymphoma; 2002 Feb; 43(2):219-24. PubMed ID: 11999550
[TBL] [Abstract][Full Text] [Related]
5. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
7. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y
Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells.
Shibata A; Nagaya T; Imai T; Funahashi H; Nakao A; Seo H
Breast Cancer Res Treat; 2002 Jun; 73(3):237-43. PubMed ID: 12160329
[TBL] [Abstract][Full Text] [Related]
9. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis.
Ushio-Fukai M; Tang Y; Fukai T; Dikalov SI; Ma Y; Fujimoto M; Quinn MT; Pagano PJ; Johnson C; Alexander RW
Circ Res; 2002 Dec; 91(12):1160-7. PubMed ID: 12480817
[TBL] [Abstract][Full Text] [Related]
10. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
[TBL] [Abstract][Full Text] [Related]
11. p38 MAP kinase--a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability.
Issbrücker K; Marti HH; Hippenstiel S; Springmann G; Voswinckel R; Gaumann A; Breier G; Drexler HC; Suttorp N; Clauss M
FASEB J; 2003 Feb; 17(2):262-4. PubMed ID: 12490545
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
13. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
14. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
Harris AL
Oncologist; 2000; 5 Suppl 1():32-6. PubMed ID: 10804089
[TBL] [Abstract][Full Text] [Related]
15. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops.
Masood R; Kundra A; Zhu S; Xia G; Scalia P; Smith DL; Gill PS
Int J Cancer; 2003 May; 104(5):603-10. PubMed ID: 12594815
[TBL] [Abstract][Full Text] [Related]
16. von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis.
Jones MK; Szabó IL; Kawanaka H; Husain SS; Tarnawski AS
FASEB J; 2002 Feb; 16(2):264-6. PubMed ID: 11772947
[TBL] [Abstract][Full Text] [Related]
17. MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer.
Koul D; Shen R; Garyali A; Ke LD; Liu TJ; Yung WK
Int J Oncol; 2002 Sep; 21(3):469-75. PubMed ID: 12168088
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.
Bellamy WT; Richter L; Frutiger Y; Grogan TM
Cancer Res; 1999 Feb; 59(3):728-33. PubMed ID: 9973224
[TBL] [Abstract][Full Text] [Related]
20. Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability.
Eriksson A; Cao R; Roy J; Tritsaris K; Wahlestedt C; Dissing S; Thyberg J; Cao Y
Circulation; 2003 Mar; 107(11):1532-8. PubMed ID: 12654612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
